Qiagen EZ2 Extractor

The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price purchase order to Qiagen, LLC for a purchase order for Qiagen EZ2 Extraction Platform to include EZ2 Connect MDx, Connectivity Package B EZ2, EZ2 Connect Installationand Training, and EZ2Connect IQOQ Service.  This procurement will satisfy the Agency’s requirements because the EZ2 Dx extraction platform is being used to evaluate the performance of the FDA-approved in vitro diagnostic assays in conjunction with extraction on the EZ2 Dx extraction platform.  This contract action is for supplies for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b)(SAP) and 41 U.S.C. 3304(a)(1).  Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within five (5) days of the issuance of this notice will be considered by the government.  A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to contract specialist at tesslinger@cdc.gov by COB August 28, 2023.